A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

NCT00885963 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Limitation in financial resources.

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: sapacitabine

Sponsor

Cyclacel Pharmaceuticals, Inc.